News|Articles|August 5, 2014

BioSpectra Opens Contract Manufacturing Facility

BioSpectra's Pennsylvania facility will manufacture biological buffers, pharmaceutical excipients, and laboratory reagents.

BioSpectra opened an FDA-registered facility in Bangor, Pennsylvania, US for contract-manufactured products for pharmaceutical, biopharmaceutical, and drug manufacturing markets.

BioSpectra provides custom cGMP purifications, acidifications, acid/base reactions, custom formulations, and particle manipulation backed by fully-documented regulatory support using ICHQ7 manufacturing systems. The company produces biological buffers, pharmaceutical excipients, and laboratory reagents.

Source: BioSpectra


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.